Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants

被引：18

作者：

Kawade, Anand ^{[1
]}

Babji, Sudhir ^{[1
,2
]}

Kamath, Veena ^{[3
]}

Raut, Abhishek ^{[4
]}

Kumar, Chandra Mohan ^{[5
]}

Kundu, Ritabrata ^{[6
]}

Venkatramanan, Padmasani ^{[7
]}

Lalwani, Sanjay K. ^{[8
]}

Bavdekar, Ashish ^{[1
]}

Juvekar, Sanjay ^{[1
]}

Dayma, Girish ^{[1
]}

Patil, Rakesh ^{[1
]}

Kulkarni, Muralidhar ^{[3
]}

Hegde, Asha ^{[3
]}

Nayak, Dinesh ^{[3
]}

Garg, B. S. ^{[4
]}

Gupta, Subodh ^{[4
]}

Jategaonkar, Smita ^{[4
]}

Bedi, Nidhi ^{[5
]}

Maliye, Chetna ^{[4
]}

Ganguly, Nupur ^{[6
]}

Uttam, Kheya Ghosh ^{[6
]}

Niyogi, Prabal ^{[6
]}

Palkar, Sonali ^{[8
]}

Hanumante, Neeta ^{[8
]}

Goyal, Nidhi ^{[9
]}

Arya, Alok ^{[9
]}

Aslam, Mohd. ^{[9
]}

Paruiekar, Varsha ^{[10
]}

Dharmadhikari, Abhijeet ^{[11
]}

Gaikwad, Dutta ^{[11
]}

Zade, Jagdish ^{[11
]}

Desai, Sajjad ^{[11
]}

Kang, Gagandeep ^{[2
]}

Kulkarni, Prasad S. ^{[11
]}

机构：

[1] KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India

[2] Christian Med Coll Vellore, Wellcome Trust Res Lab, Vellore, Tamil Nadu, India

[3] Manipal Acad Higher Educ, Manipal, Karnataka, India

[4] Mahatma Gandhi Inst Med Sci, Sevagram, India

[5] Hamdard Inst Med Sci & Res, Delhi, India

[6] Inst Child Hlth Kolkata, Kolkata, India

[7] Sri Ramachandra Med Ctr, Chennai, Tamil Nadu, India

[8] Bharati Vidyapeeth Med Coll & Hosp, Pune, Maharashtra, India

[9] Soc Appl Studies, Ctr Hlth Res & Dev, Delhi, India

[10] DiagnoSearch Life Sci Pvt Ltd, Mumbai, Maharashtra, India

[11] Serum Inst India Pvt Ltd, 212-2 Hadapsar, Pune, Maharashtra, India

来源：

VACCINE | 2019年 / 37卷 / 19期

关键词：

Liquid Bovine-Human Reassortant; Pentavalent Rotavirus Vaccine (LBRV-PV); Lot-to-lot consistency; Immunogenicity; Safety; SAFETY; IMPACT; MORTALITY; EFFICACY; CHILDREN; TRIAL; COST;

D O I：

10.1016/j.vaccine.2019.03.067

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Background: A lyophilized bovine-human rotavirus reassortant pentavalent vaccine (BRV-PV, Rotasiil (R)) was licensed in 2016. A liquid formulation of this vaccine (LBRV-PV, Rotasiil - Liquid) was subsequently developed and was tested for non-inferiority to Rotasiil (R) and for lot-to-lot consistency. Methods: This Phase open II/III, randomized study was conducted at seven sites across India from November 2017 to June 2018. Participants were randomized into four arms; Lots A, B, and C of LBRV-PV and Rotasiil (R) in 1:1:1:1 ratio. Three doses of study vaccines were given at 6, 10, and 14 weeks of age. Blood samples were collected four weeks after the third dose to assess rotavirus IgA antibody levels. Non-inferiority of LBRV-PV to Rotasiil was proven if the lower limit two-sided 95% confidence interval (CI) of geometric mean concentration (GMC) ratio was at least 0.5. Lot-to-lot consistency was proven if 95% CI of the GMC ratios of three lots were between 0.5 and 2. Solicited reactions were collected by using diary cards. Results: Of the 1500 randomized infants, 1436 infants completed the study. The IgA GMC ratio of LBRV-PV to Rotasiil (R) was 1.19 (95% CI 0.96, 1.48). The corresponding IgA seropositivity rates were 60.41% (57.41, 63.35) and 52.75% (47.48, 57.97). The IgA GMC ratios among the three LBRV-PV lots were: Lot A versus Lot B: 1.34 (1.03, 1.75); Lot A versus Lot C: 1.22 (0.93, 1.60); and Lot B versus Lot C: 0.91 (0.69, 1.19). The 95% Cls for the GMC ratios were between 0.69 and 1.75. The incidence of solicited reactions was comparable across the four arms. Only one serious adverse event of gastroenteritis event in the Rotasiil (R) group was causally related. Conclusion: The immunological non-inferiority of LBRV-PV against Rotasiil as well as lot-to-lot consistency of LBRV-PV was demonstrated. LBRV-PV had safety profile similar to Rotasiil (R). (C) 2019 Elsevier Ltd. All rights reserved.

引用

页码：2554 / 2560

页数：7

共 45 条

[21] Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III, observer blind, randomized, controlled clinical study
Zaman, Khalequ
Kingma, Robert
Yunus, Md
van Straaten, Ineke
Mekkes, Dirk
Bouwstra, Xandra
Gunale, Bhagwat
Kulkarni, Prasad S.
VACCINE, 2019, 37 (31) : 4275 - 4280
[22] Pentavalent human-bovine reassortant rotavirus vaccine: A review of its efficacy and safety in preventing acute rotavirus gastroenteritis in healthy infants
Caple, Jane
DRUGS OF TODAY, 2006, 42 (05) : 313 - 319
[23] Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwP-HepB-Hib vaccine: Results from Phase III licensure study of Shan5TM
Sil, A.
Patnaik, B. N.
Midde, V. J.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 45 : 43 - 43
[24] Shedding of oral pentavalent bovine-human reassortant rotavirus vaccine indicates high uptake rate of vaccine and prominence of G-type G1
Markkula, Jukka
Hemming-Harlo, Maria
Vesikari, Timo
VACCINE, 2020, 38 (06) : 1378 - 1383
[25] Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life
Block, Stan L.
Vesikari, Timo
Goveia, Michelle G.
Rivers, Stephen B.
Adeyi, Ben A.
Dallas, Michael J.
Bauder, Jeffrey
Boslego, John W.
Heaton, Penny M.
PEDIATRICS, 2007, 119 (01) : 11 - 18
[26] Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants
Goveia, Michelle G.
Rodriguez, Zoe M.
Dallas, Michael J.
Itzler, Robbin F.
Boslego, John W.
Heaton, Penny M.
DiNubile, Mark J.
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (12) : 1099 - 1104
[27] Safety, Immunogenicity and Lot-to-Lot Consistency of Sabin-Strain Inactivated Poliovirus Vaccine in 2-Month-Old Infants: A Double-Blind, Randomized Phase III Trial
Zheng, Yan
Ying, Zhifang
Zou, Yanxiang
Zhu, Taotao
Qian, Dinggu
Han, Weixiao
Jiang, Ya
Jiang, Zhiwei
Li, Xingyan
Wang, Jianfeng
Lei, Jin
Xu, Li
Jiang, Deyu
Li, Changgui
Liu, Xiaoqiang
VACCINES, 2022, 10 (02)
[28] Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants
Clements-Mann, ML
Dudas, R
Hoshino, Y
Nehring, P
Sperber, E
Wagner, M
Stephens, I
Karron, R
Deforest, A
Kapikian, AZ
VACCINE, 2001, 19 (32) : 4676 - 4684
[29] Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months
Feng, Guangwei
Jiang, Deyu
Han, Weixiao
Xie, Zhiqiang
Jiang, Zhiwei
Huang, Lili
Wang, Jianfeng
Zhang, Wei
Xu, Li
Tan, Jiebing
You, Wangyang
Cui, Guoliang
Li, Changgui
Wang, Yanxia
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : 20 - 27
[30] Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): Randomized, controlled phase III study in Indian infants
Saluja, Tarun
Palkar, Sonali
Misra, Puneet
Gupta, Madhu
Venugopal, Potula
Sood, Ashwani Kumar
Dhati, Ravi Mandyam
Shetty, Avinash
Dhaded, Sangappa Malappa
Agarkhedkar, Sharad
Choudhury, Amlan
Kumar, Ramesh
Balasubramanian, Sundaram
Babji, Sudhir
Adhikary, Lopa
Dupuy, Martin
Chadha, Sangeet Mohan
Desai, Forum
Kukian, Darshna
Patnaik, Badri Narayan
Dhingra, Mandeep Singh
VACCINE, 2017, 35 (28) : 3575 - 3581

← 1 2 3 4 5 →